ADMA חוב כולל להון ADMA Corp

ADMA Biologics (ADMA) is a vital brand producing plasma-derived therapies for immunodeficient patients and commanding immense respect from physicians. Historical price action on GURU.Markets shows that the debt-to-equity ratio is 0.46. Production relies on strict FDA regulations and a qualified staff of laboratory technicians. However, dependence on donor activity and competitive pressure create certain operational challenges.

Investors view ADMA Biologics (ADMA) as a promising asset, where the calculation logic of the 0.46 metric determines the balance between external liabilities and equity to assess financial stability. An analysis of the debt-to-equity chart confirms the company's ability to fund the modernization of plasma fractionation processes without a critical debt load, characterizing the securities as a fundamentally balanced instrument.